{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:57Z","timestamp":1792723137028,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.biopha.2020.111087","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T13:19:21Z","timestamp":1607433561000},"page":"111087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-4320","authenticated-orcid":false,"given":"Pablo","family":"Zubiaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-2626","authenticated-orcid":false,"given":"Paula","family":"Soria-Chacartegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-0466","authenticated-orcid":false,"given":"Dora","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-6845","authenticated-orcid":false,"given":"Marcos","family":"Navares-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Almenara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-3135","authenticated-orcid":false,"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-3268","authenticated-orcid":false,"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Mart\u00edn-V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.111087_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/bmj.39227.616447.BE","article-title":"Schizophrenia","volume":"335","author":"Picchioni","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2020.111087_bib0010","first-page":"1","article-title":"Epidemiology and risk factors of schizophrenia","volume":"37","author":"Janoutov\u00e1","year":"2016","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.biopha.2020.111087_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.biopha.2020.111087_bib0020","first-page":"178","article-title":"Comparison of olanzapine versus other second-generation antipsychotics in the improvement of insight and medication discontinuation rate in schizophrenia","volume":"30","author":"He","year":"2018","journal-title":"Shanghai Arch. Psychiatry"},{"key":"10.1016\/j.biopha.2020.111087_bib0025","unstructured":"European Medicines Agency Zyprexa, olanzapine drug label."},{"key":"10.1016\/j.biopha.2020.111087_bib0030","first-page":"539","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants: pharmacogenet","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Genomics"},{"key":"10.1016\/j.biopha.2020.111087_bib0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine: pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2020.111087_bib0040","unstructured":"KNMP CYP2D6: olanzapine."},{"key":"10.1016\/j.biopha.2020.111087_bib0045","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14300","article-title":"The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple\u2010dose trial","author":"Koller","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111087_bib0050","article-title":"Safety and cardiovascular effects of multiple\u2010dose administration of aripiprazole and olanzapine in a randomised clinical trial","author":"Koller","year":"2020","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.biopha.2020.111087_bib0055","unstructured":"European Medicines Agency ICH E6 (R2) Good clinical practice."},{"key":"10.1016\/j.biopha.2020.111087_bib0060","unstructured":"AEMPS NORMAS DE BUENA PR\u00c1CTICA CLINICA. Disponible en internet. Consultado el 20-05-2020."},{"key":"10.1016\/j.biopha.2020.111087_bib0065","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.biopha.2020.111087_bib0070","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"94","key":"10.1016\/j.biopha.2020.111087_bib0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.111087_bib0080","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and efavirenz\u2010containing antiretroviral therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.111087_bib0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti\u2010inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.111087_bib0090","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cpt.1007","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy","volume":"103","author":"Goetz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.111087_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"96","key":"10.1016\/j.biopha.2020.111087_bib0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.111087_bib0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/biomedicines8040094","article-title":"Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates","volume":"8","author":"Saiz-Rodr\u00edguez","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2020.111087_bib0110","first-page":"28","article-title":"CYP3A4\/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control","author":"Kitzmiller","year":"2013","journal-title":"Drug Metabol. Drug Interact."},{"key":"10.1016\/j.biopha.2020.111087_bib0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0269881119827959","article-title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics","volume":"33","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.biopha.2020.111087_bib0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.2308","article-title":"Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects: OLANZAPINE PHARMACOGENETICS","volume":"28","author":"Cabaleiro","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.biopha.2020.111087_bib0125","series-title":"Qualigen 10 Mg Comprimidos Recubiertos Con Pel\u00edcula EFG","author":"AEMPS Olanzapina","year":"2020"},{"key":"10.1016\/j.biopha.2020.111087_bib0130","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mp.2011.38","article-title":"Genetic variation in CYP3A43 explains racial difference in olanzapine clearance","volume":"16","author":"Bigos","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2020.111087_bib0135","first-page":"3","article-title":"Sex-linked regulation of CYP1A2 in adult human cultured hepatocytes","author":"Thangavel","year":"2018","journal-title":"Pharmacol. Drug Dev. Ther."},{"key":"10.1016\/j.biopha.2020.111087_bib0140","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002280100343","article-title":"Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes","volume":"57","author":"H\u00e4gg","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111087_bib0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00041444-200203000-00008","article-title":"CYP2D6 polymorphisms and atypical antipsychotic weight gain","volume":"12","author":"Ellingrod","year":"2002","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.biopha.2020.111087_bib0150","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1124\/dmd.115.064790","article-title":"In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism","volume":"43","author":"Korprasertthaworn","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2020.111087_bib0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: clozapine pathway, pharmacokinetics","volume":"28","author":"Thorn","year":"2018","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.biopha.2020.111087_bib0160","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/pgs-2017-0095","article-title":"OCT1 pharmacogenetics in pain management: is a clinical application within reach?","volume":"18","author":"Tzvetkov","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2020.111087_bib0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/17425255.2.3.351","article-title":"Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition","volume":"2","author":"Jedlitschky","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2020.111087_bib0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/tpj.2012.37","article-title":"Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy","volume":"13","author":"Simon","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.biopha.2020.111087_bib0175","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jcph.1252","article-title":"A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006\/Sarcoma-09 trial","volume":"58","author":"Lui","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111087_bib0180","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/0269881118798605","article-title":"Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects","volume":"32","author":"Koller","year":"2018","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.biopha.2020.111087_bib0185","doi-asserted-by":"crossref","DOI":"10.2217\/pgs-2018-0101","article-title":"How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?","author":"Zubiaur","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2020.111087_bib0190","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2020.111087_bib0195","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/pgs.12.86","article-title":"Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective","volume":"13","author":"Vijayan","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2020.111087_bib0200","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans: efavirenz population pharmacokinetic\/pharmacogenetic modelling","volume":"68","author":"Mukonzo","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111087_bib0205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.tpj.6500474","article-title":"Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia","volume":"8","author":"Smith","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.biopha.2020.111087_bib0210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.tpj.6500474","article-title":"Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia","volume":"8","author":"Smith","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.biopha.2020.111087_bib0215","first-page":"569","article-title":"DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia:Pharmacogenet","volume":"20","author":"Lencz","year":"2010","journal-title":"Genomics"},{"key":"10.1016\/j.biopha.2020.111087_bib0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","article-title":"Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response","volume":"32","author":"Lee","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.biopha.2020.111087_bib0225","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/pgs.14.68","article-title":"Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia","volume":"15","author":"Ceppi","year":"2014","journal-title":"Pharmacogenomics"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220312804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220312804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:03:06Z","timestamp":1792720986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220312804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":45,"alternative-id":["S0753332220312804"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111087","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111087"}}